{
    "clinical_study": {
        "@rank": "72004", 
        "arm_group": {
            "arm_group_label": "doxorubicin/cyclophosphamide", 
            "arm_group_type": "Experimental", 
            "description": "Neoadjuvant Chemotherapy with Docetaxel(Monotaxel\u00ae) after Doxorubicin plus Cyclophosphamide"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, open-label, phase IV trial to assess the efficacy and safety of\n      sequential neoadjuvant chemotherapy with 4 cycles of doxorubicin/cyclophosphamide followed\n      by 4 cycles of docetaxel(Monotaxel\u00ae) in patients with breast cancer of \u22655cm in size or\n      cytologically confirmed axillary lymph nodes metastasis."
        }, 
        "brief_title": "An Open-label, Multi-center Phase \u2163 Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel\u00ae) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with histologically proven invasive breast cancer - the primary tumor size\n             is at least 5cm or cytologically proven axillary node metastasis\n\n          2. no evidence of systemic metastasis pathologically or radiologically\n\n          3. age at the time of diagnosis between 20 and 70 years\n\n          4. patients with previously untreated primary breast cancer including chemotherapy\n\n          5. general performance status with ECOG 0-2\n\n          6. sufficient hematopoietic function (absolute neutrophil count of \u2265 1,500/mm3, platelet\n             count of \u2265 100,000/mm3, and hemoglobin of \u2265 10 g/dL)\n\n          7. sufficient renal function (serum creatinine level of \u2264 1.5 mg/dL)\n\n          8. sufficient liver function (total serum bilirubin level \u2264 1.5 times the upper normal\n             limit; serum AST and ALT levels \u2264 1.5 times the upper normal limit; and serum\n             alkaline phosphatase level \u2264 1.5 times the upper normal limit)\n\n          9. sufficient cardiac function (normal electrocardiography within 1 month or LVEF>50% by\n             echocardiography or MUGA scan within 3 months)\n\n         10. patients who agree to enroll this clinical trial and sign the written informed\n             consent voluntarily\n\n        Exclusion Criteria:\n\n          1. patients with evidence of distant metastases\n\n          2. patients with other previous malignancy except breast cancer\n\n          3. pregnant (positive hCG test 1 week before registration) or lactating patient\n\n          4. uncontrolled serious infection\n\n          5. patients with psychiatric disease or epilepsy\n\n          6. patients with clinically severe cardiac disease within 6 months such as atrial or\n             ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable\n             angina\n\n          7. male breast cancer\n\n          8. patients with poor general condition who are not able to understand or sign the\n             written informed consent"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660542", 
            "org_study_id": "4-2011-0068"
        }, 
        "intervention": {
            "arm_group_label": "doxorubicin/cyclophosphamide", 
            "description": "Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles", 
            "intervention_name": "Neoadjuvant Chemotherapy with Docetaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Docetaxel", 
                "Doxorubicin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "PSH1025@yuhs.ac", 
                "last_name": "Se Ho Park, MD", 
                "phone": "82-2-2228-2134"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "120-752"
                }, 
                "name": "Severance hospital"
            }, 
            "investigator": {
                "last_name": "Byeong-Woo Park, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Pathologic complete response is defined as the disappearance of all invasive cancer in the postsurgical breast and lymph node specimens after completion of neoadjuvant chemotherapy. Only residual intraductal carcinoma in the postsurgical breast specimen after neoadjuvant chemotherapy is also considered as the achievement of pathologic complete response.", 
            "measure": "Pathologic Complete Response", 
            "safety_issue": "No", 
            "time_frame": "26 weeks after the first administration of neoadjuvant chemotherapy with doxorubicin/cyclophosphamide regimens"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660542"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Yonsei University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yonsei University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}